Williams Neal K, Lucet Isabelle S, Klinken S Peter, Ingley Evan, Rossjohn Jamie
Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia, and the Laboratory for Cancer Medicine and Cell Signalling Group, Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Perth, Western Australia 6000, Australia.
Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia, and the Laboratory for Cancer Medicine and Cell Signalling Group, Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Perth, Western Australia 6000, Australia; Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3800, Australia, and the Laboratory for Cancer Medicine and Cell Signalling Group, Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Perth, Western Australia 6000, Australia.
J Biol Chem. 2009 Jan 2;284(1):284-291. doi: 10.1074/jbc.M807850200. Epub 2008 Nov 4.
The Src-family protein-tyrosine kinase (PTK) Lyn is the most important Src-family kinase in B cells, having both inhibitory and stimulatory activity that is dependent on the receptor, ligand, and developmental context of the B cell. An important role for Lyn has been reported in acute myeloid leukemia and chronic myeloid leukemia, as well as certain solid tumors. Although several Src-family inhibitors are available, the development of Lyn-specific inhibitors, or inhibitors with reduced off-target activity to Lyn, has been hampered by the lack of structural data on the Lyn kinase. Here we report the crystal structure of the non-liganded form of Lyn kinase domain, as well as in complex with three different inhibitors: the ATP analogue AMP-PNP; the pan Src kinase inhibitor PP2; and the BCR-Abl/Src-family inhibitor Dasatinib. The Lyn kinase domain was determined in its "active" conformation, but in the unphosphorylated state. All three inhibitors are bound at the ATP-binding site, with PP2 and Dasatinib extending into a hydrophobic pocket deep in the substrate cleft, thereby providing a basis for the Src-specific inhibition. Analysis of sequence and structural differences around the active site region of the Src-family PTKs were evident. Accordingly, our data provide valuable information for the further development of therapeutics targeting Lyn and the important Src-family of kinases.
Src家族蛋白酪氨酸激酶(PTK)Lyn是B细胞中最重要的Src家族激酶,其抑制和刺激活性取决于B细胞的受体、配体和发育环境。Lyn在急性髓系白血病、慢性髓系白血病以及某些实体瘤中发挥重要作用。尽管已有几种Src家族抑制剂,但由于缺乏Lyn激酶的结构数据,Lyn特异性抑制剂或对Lyn具有降低脱靶活性的抑制剂的开发受到阻碍。在此,我们报告了Lyn激酶结构域的非配体形式以及与三种不同抑制剂复合物的晶体结构:ATP类似物AMP-PNP;泛Src激酶抑制剂PP2;以及BCR-Abl/Src家族抑制剂达沙替尼。Lyn激酶结构域以其“活性”构象确定,但处于未磷酸化状态。所有三种抑制剂都结合在ATP结合位点,PP2和达沙替尼延伸到底物裂隙深处的疏水口袋中,从而为Src特异性抑制提供了基础。Src家族PTK活性位点区域周围的序列和结构差异很明显。因此,我们的数据为进一步开发靶向Lyn和重要Src激酶家族的疗法提供了有价值的信息。